Cutia Therapeutics (HKSE:02487) ROCE % : -214.51% (As of Jun. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Cutia Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cutia Therapeutics's annualized ROCE % for the quarter that ended in Jun. 2023 was -214.51%.

Cutia Therapeutics ROCE % Historical Data

The historical data trend for Cutia Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cutia Therapeutics ROCE % Chart

Cutia Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

ROCE %

-21.62

-37.10

-137.49

Cutia Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	-	-32.57	-44.27	-214.51	-41.25

Cutia Therapeutics ROCE % Calculation

Cutia Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-618.781	/	( ( (1830.433 - 23.571)	+	(1615.668 - 86.436) )	/ 2 )
	=	-618.781	/	( (1806.862	+	1529.232)	/ 2 )
	=	-618.781	/	1668.047
	=	-37.10 %

Cutia Therapeutics's ROCE % of for the quarter that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	-3584.588	/	( ( (1615.668 - 86.436)	+	(1956.596 - 143.666) )	/ 2 )
	=	-3584.588	/	( ( 1529.232	+	1812.93 )	/ 2 )
	=	-3584.588	/	1671.081
	=	-214.51 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2023) EBIT data.

Cutia Therapeutics (HKSE:02487) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cutia Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Cutia Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cutia Therapeutics (HKSE:02487) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cutia Therapeutics (HKSE:02487) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

436 Heng Feng Road, 20th Floor, Huanzhi Building, Jingan District, Shanghai, CHN, 200070

Website

https://www.cutiatx.com

Cutia Therapeutics is a dermatology-focused biopharmaceutical company focused on the broader dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. Its core product is CU-20401, which is a recombinant mutant collagenase that targets obesity, overweight, or other localized adipose accumulation-associated metabolic diseases.

Executives

Pandanus Associates Inc.	2201 Interest of corporation controlled by you
Pandanus Partners L.p.	2201 Interest of corporation controlled by you
Fil Limited	2201 Interest of corporation controlled by you
Shen Nan Peng	2201 Interest of corporation controlled by you
Snp China Enterprises Limited	2201 Interest of corporation controlled by you
Hongshan Capital Growth Fund V, L.p.	2201 Interest of corporation controlled by you
Hsg Growth V Holdco Q, Ltd	2201 Interest of corporation controlled by you
Hsg Growth V Management, L.p.	2201 Interest of corporation controlled by you
Hsg Holding Limited	2201 Interest of corporation controlled by you
Ma Yun	2201 Interest of corporation controlled by you
Su Zhou Tong Yu Tou Zi Guan Li He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Su Zhou Yun Zhang Tou Zi Zi Xun You Xian Gong Si	2201 Interest of corporation controlled by you
Su Zhou Tong He Er Qi Chuang Ye Tou Zi He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Su Zhou Fu Yan Chuang Ye Tou Zi Guan Li He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Aurora Cutis Limited	2301 Trustee

Cutia Therapeutics (HKSE:02487) Headlines

No Headlines